Subtype
Female Reproductive System Carcinoma
CI-CAN-00002685Explore in graph →
458 active trials5 approved drugs36 evidence items
- NCIt
- C181162
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002685Explore in graph →
Clinical trials
1,481 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (201)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04209855 | A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression(MIRASOL) | completed | Phase 3 | 453 | AbbVieINDUSTRY | 21 | Aug 27, 2025 | clinicaltrials |
| NCT04159155 | A Study of Various Treatments in Serous or p53 Abnormal Endometrial Cancer(CAN-STAMP) | terminated | Phase 2 / Phase 3 | 11 | University Health Network, Toronto |
| 1 |
| Aug 12, 2025 |
| clinicaltrials |
| NCT03728881 | Single Dose of Cervarix Vaccine in Girls or Three Doses of Gardasil Vaccine in Women for the Prevention of Human Papillomavirus Infection, the PRIMAVERA-ESCUDDO Trial(PRIMAVERA) | completed | Phase 3 | 1,240 | National Cancer Institute (NCI)NIH | 1 | Aug 3, 2025 | clinicaltrials |
| NCT03522246 | A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy(ATHENA) | active not recruiting | Phase 3 | 1,097 | pharmaand GmbHINDUSTRY | 24 | Jun 24, 2025 | clinicaltrials |
| NCT01101451 | Radiation Therapy With or Without Chemotherapy in Patients With Stage I-IIA Cervical Cancer Who Previously Underwent Surgery | completed | Phase 3 | 340 | GOG FoundationNETWORK | 3 | May 23, 2025 | clinicaltrials |
| NCT03201861 | Addition of Cisplatin to Adjuvant Chemotherapy for Early Stage Breast Cancer in High-Risk Women | recruiting | Phase 3 | 762 | RenJi HospitalOTHER | 1 | May 16, 2025 | clinicaltrials |
| NCT03353831 | Atezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian Cancer | completed | Phase 3 | 574 | AGO Research GmbHINDUSTRY | 12 | Apr 6, 2025 | clinicaltrials |
| NCT02641639 | FOCUS: PCC + Bevacizumab + CA4P Versus PCC + Bevacizumab + Placebo for Subjects With Platinum Resistant Ovarian Cancer | terminated | Phase 2 / Phase 3 | 70 | Mateon TherapeuticsINDUSTRY | 3 | Mar 24, 2025 | clinicaltrials |
| NCT04421547 | Efficacy of Letrozole in Recurrent Ovarian Cancer(MITO32) | terminated | Phase 3 | 86 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Mar 7, 2025 | clinicaltrials |
| NCT05737303 | Nab-paclitaxel Versus Sb-taxanes As First-Line Treatment in Advanced Ovarian Cancer | recruiting | Phase 3 | 538 | Women's Hospital School Of Medicine Zhejiang UniversityOTHER | 1 | Feb 11, 2025 | clinicaltrials |
| NCT02859038 | Study of Upfront Surgery Versus Neoadjuvant Chemotherapy in Patients With Advanced Ovarian Cancer (SUNNY) | active not recruiting | Phase 3 | 489 | Shanghai Gynecologic Oncology GroupOTHER_GOV | 2 | Feb 10, 2025 | clinicaltrials |
| NCT06781073 | Nimotuzumab in Combined With Chemotherapy for Treatment of IVB Stage,Rrecurrent or Persistent Cervical Carcinoma | completed | Phase 3 | 118 | Biotech Pharmaceutical Co., Ltd.OTHER | 1 | Jan 17, 2025 | clinicaltrials |
| NCT03598270 | Platinum-based Chemotherapy With Atezolizumab and Niraparib in Patients With Recurrent Ovarian Cancer(ANITA) | completed | Phase 3 | 417 | Grupo Español de Investigación en Cáncer de OvarioOTHER | 5 | Aug 30, 2024 | clinicaltrials |
| NCT03949283 | Cancer Stem Cell Assay Directed Chemotherapy in Recurrent Platinum Resistant Ovarian Cancer | active not recruiting | Phase 3 | 150 | Cordgenics, LLCINDUSTRY | 1 | Aug 22, 2024 | clinicaltrials |
| NCT05235516 | A Study of AK104/Placebo Combined With Chemoradiotherapy For The Treatment of Locally Advanced Cervical Cancer(AK104-305) | active not recruiting | Phase 3 | 636 | AkesoINDUSTRY | 1 | Aug 13, 2024 | clinicaltrials |
| NCT04296890 | A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression(SORAYA) | completed | Phase 3 | 106 | ImmunoGen, Inc.INDUSTRY | 11 | Aug 7, 2024 | clinicaltrials |
| NCT06539091 | Fluzoparib in Combination With Apatinib Mesylate for Maintenance Therapy in Stage III-IV Ovarian Cancer | not yet recruiting | Phase 3 | 51 | Anhui Provincial HospitalOTHER_GOV | 0 | Aug 6, 2024 | clinicaltrials |
| NCT02501954 | Trial of Cisplatin Plus Radiation Followed by Carbo and Taxol Vs. Sandwich Therapy of Carbo and Taxol Followed Radiation Then Further Carbo and Taxol | completed | Phase 3 | 48 | Women's Cancer Care Associates, LLCOTHER | 2 | Jul 23, 2024 | clinicaltrials |
| NCT04676334 | CATCH-R: A Rollover Study to Provide Continued Access to Rucaparib(CATCH-R) | completed | Phase 3 | 34 | pharmaand GmbHINDUSTRY | 6 | May 7, 2024 | clinicaltrials |
| NCT06341907 | Application of MRD Combined With Personalized Vaccine in the Treatment of Postoperative Recurrence Prevention of EOC | recruiting | Phase 2 / Phase 3 | 10 | Second Affiliated Hospital of Wenzhou Medical UniversityOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT02584478 | Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002)(AL3818) | unknown | Phase 3 | 294 | Advenchen Laboratories, LLCINDUSTRY | 6 | Nov 8, 2023 | clinicaltrials |
| NCT05712941 | Comparison of Letrozole With Lerociclib Versus Letrozole With Placebo Control in Patients With Advanced/Metastatic or Recurrent, Grade 1 or Grade 2 Endometrial Cancer | withdrawn | Phase 3 | 0 | EQRx International, Inc.INDUSTRY | 0 | Nov 3, 2023 | clinicaltrials |
| NCT01849874 | A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer | terminated | Phase 3 | 341 | PfizerINDUSTRY | 19 | Oct 30, 2023 | clinicaltrials |
| NCT04729608 | Batiraxcept (AVB-S6-500)/Placebo in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer(AXLerate-OC) | terminated | Phase 3 | 366 | Aravive, Inc.INDUSTRY | 11 | Oct 30, 2023 | clinicaltrials |
| NCT05329545 | Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT)(UP-NEXT) | terminated | Phase 3 | 20 | Mersana TherapeuticsINDUSTRY | 3 | Oct 26, 2023 | clinicaltrials |
| NCT01506856 | Intraperitoneal Therapy For Ovarian Cancer With Carboplatin Trial(iPocc) | completed | Phase 2 / Phase 3 | 655 | Gynecologic Oncology Trial & Investigation ConsortiumNETWORK | 6 | Sep 15, 2023 | clinicaltrials |
| NCT02221999 | Weekly Paclitaxel and Cisplatin to Treat Hormone Receptor Positive and Triple Negative Breast Cancer Patients(SHPD002) | active not recruiting | Phase 2 / Phase 3 | 250 | RenJi HospitalOTHER | 1 | Aug 29, 2023 | clinicaltrials |
| NCT04201561 | High Dose Inorganic Selenium for Preventing Chemotherapy Induced Peripheral Neuropathy(SELENIUM) | unknown | Phase 3 | 68 | Seoul National University HospitalOTHER | 1 | Jun 26, 2023 | clinicaltrials |
| NCT02855944 | ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients | completed | Phase 3 | 349 | pharmaand GmbHINDUSTRY | 12 | Jun 9, 2023 | clinicaltrials |
| NCT01847274 | A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer | completed | Phase 3 | 596 | Tesaro, Inc.INDUSTRY | 15 | Jun 2, 2023 | clinicaltrials |
| NCT03398655 | A Study of VB-111 With Paclitaxel vs Paclitaxel for Treatment of Recurrent Platinum-Resistant Ovarian Cancer (OVAL)(OVAL) | completed | Phase 3 | 408 | Vascular Biogenics Ltd. operating as VBL TherapeuticsINDUSTRY | 5 | Jan 10, 2023 | clinicaltrials |
| NCT05622890 | A Single-arm Clinical Trial of IMGN853 in Chinese Adult Patients With Platinum-resistant, Epithelial Ovarian Cancer | unknown | Phase 3 | 35 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 21, 2022 | clinicaltrials |
| NCT01414608 | Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer | completed | Phase 3 | 926 | GOG FoundationNETWORK | 5 | Nov 7, 2022 | clinicaltrials |
| NCT03106987 | A Study to Examine Olaparib Maintenance Retreatment in Patients With Epithelial Ovarian Cancer.(OReO) | completed | Phase 3 | 220 | AstraZenecaINDUSTRY | 11 | Oct 7, 2022 | clinicaltrials |
| NCT04795596 | Secondary Cytoreductive Surgery in Platinum-resistant Recurrent Ovarian Cancers | withdrawn | Phase 2 / Phase 3 | 0 | Menoufia UniversityOTHER | 1 | Apr 15, 2022 | clinicaltrials |
| NCT03690739 | Evaluation of Symptom Benefit Rate of Trabectedin/PLD in Patients With Recurrent Ovarian Cancer | terminated | Phase 3 | 9 | AGO Research GmbHINDUSTRY | 1 | Feb 24, 2022 | clinicaltrials |
| NCT05145218 | A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus Paclitaxel as Weekly Treatment of Relapsed Platinum-resistant Ovarian Cancer | unknown | Phase 3 | 405 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Dec 8, 2021 | clinicaltrials |
| NCT00942357 | Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer | unknown | Phase 3 | 813 | Gynecologic Oncology GroupNETWORK | 3 | Oct 19, 2021 | clinicaltrials |
| NCT00108745 | Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer | unknown | Phase 3 | 1,157 | GOG FoundationNETWORK | 1 | Sep 30, 2021 | clinicaltrials |
| NCT00954174 | Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer | unknown | Phase 3 | 637 | GOG FoundationNETWORK | 2 | Sep 30, 2021 | clinicaltrials |
| NCT02065687 | Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer | unknown | Phase 2 / Phase 3 | 469 | Gynecologic Oncology GroupNETWORK | 1 | Sep 30, 2021 | clinicaltrials |
| NCT01837251 | Evaluation of Optimal Treatment With Bevacizumab in Patients With Platinum-sensitive Recurrent Ovarian Cancer | completed | Phase 3 | 682 | AGO Research GmbHINDUSTRY | 6 | Jul 13, 2021 | clinicaltrials |
| NCT01611766 | Surgery or Chemotherapy in Recurrent Ovarian Cancer (SOC 1 Trial)? | unknown | Phase 3 | 356 | Shanghai Gynecologic Oncology GroupOTHER_GOV | 1 | Jun 10, 2021 | clinicaltrials |
| NCT01365156 | Extraperitoneal Para-aortic Lymph Node Dissection (EPLND) for Cervix | completed | Phase 3 | 28 | M.D. Anderson Cancer CenterOTHER | 2 | Feb 3, 2021 | clinicaltrials |
| NCT02631876 | A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer(FORWARD I) | completed | Phase 3 | 366 | ImmunoGen, Inc.INDUSTRY | 13 | Oct 14, 2020 | clinicaltrials |
| NCT04473339 | A Randomized Prospective Trail of HIPEC in Recurrent Ovarian Cancer Patients With HRR Mutation | unknown | Phase 3 | 280 | CAI HongbingOTHER | 1 | Sep 9, 2020 | clinicaltrials |
| NCT04515602 | Stratified Evaluation of PDS and NACT-IDS in Ovarian Cancer (FOCUS) | not yet recruiting | Phase 3 | 410 | Shanghai Gynecologic Oncology GroupOTHER_GOV | 1 | Aug 27, 2020 | clinicaltrials |
| NCT01583426 | Nanoparticle-based Paclitaxel vs Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Early Breast Cancer (GeparSepto)(GeparSepto) | completed | Phase 3 | 1,229 | GBG Forschungs GmbHOTHER | 1 | Aug 6, 2020 | clinicaltrials |
| NCT03371693 | Cytoreductive Surgery(CRS) Plus Hyperthermic Intraperitoneal Chemotherapy(HIPEC) With Lobaplatin in Advanced and Recurrent Epithelial Ovarian Cancer(HIPECOV) | unknown | Phase 3 | 112 | Zhongnan HospitalOTHER | 1 | May 29, 2020 | clinicaltrials |
| NCT02879513 | Trial of Adjuvant Chemotherapy in Breast Cancer Patients With Pathological Partial Response and Complete Response to Neoadjuvant Chemotherapy | unknown | Phase 3 | 290 | RenJi HospitalOTHER | 1 | Mar 23, 2020 | clinicaltrials |
Data updated 23 days agoSource updated Aug 27, 2025source: clinicaltrials